Does Cigna Cover Actos (Pioglitazone)?

Cigna Formulary Placement for Pioglitazone

Generic pioglitazone sits on a preferred tier in most Cigna commercial formulary lists, which means low out-of-pocket costs for members. The brand-name version, Actos, lost patent exclusivity in 2012, and that shift reshaped how insurers handle the drug. Generic versions now dominate formulary placement.

On standard Cigna Open Access Plus and Performance plans, pioglitazone 15 mg, 30 mg, and 45 mg tablets appear on tier 1 (preferred generic) or tier 2 (non-preferred generic) depending on the specific plan document. Tier 1 copays on Cigna commercial plans commonly range from $0 to $10 for a 30-day supply at a network pharmacy. Tier 2 placement may push costs to $10 to $25. Brand Actos, when dispensed instead of the generic, can land on tier 3 (preferred brand) or higher, with copays of $30 to $60 or coinsurance of 25% to 50%.

Cigna updates its Standard Pharmacy List and Performance Pharmacy List at least quarterly. A drug's tier can shift mid-year during these updates. Members should verify placement through the Cigna drug list lookup tool or by calling the number on the back of their ID card. Employer-sponsored plans may use a custom formulary that deviates from Cigna's standard tiers. The American Diabetes Association Standards of Care (2024) lists thiazolidinediones including pioglitazone as a second- or third-line agent for type 2 diabetes, which supports formulary inclusion across most commercial plans.

Pioglitazone's low generic cost makes it one of the most affordable branded-to-generic conversions in the diabetes drug class. That generic pricing is a major reason Cigna rarely restricts access for on-label type 2 diabetes use.

Prior Authorization Requirements

Cigna requires prior authorization for pioglitazone in two main scenarios: when a prescriber writes for brand Actos specifically (rather than the generic) and when the drug is prescribed off-label for conditions such as nonalcoholic steatohepatitis (NASH). On-label generic pioglitazone for type 2 diabetes typically does not require PA.

The PA criteria Cigna applies generally include confirmation of a type 2 diabetes diagnosis (ICD-10 E11.x), documented trial of or contraindication to metformin, and recent HbA1c values demonstrating inadequate glycemic control. For off-label NASH use, Cigna's medical policy may require liver biopsy or imaging confirming steatohepatitis, evidence that lifestyle modifications were attempted, and supporting clinical literature.

The PIVENS trial (N=247) published in the New England Journal of Medicine showed pioglitazone 30 mg daily significantly improved hepatic steatosis and lobular inflammation compared to placebo in patients with nonalcoholic steatohepatitis over 96 weeks. That trial remains a cornerstone citation when providers submit PA requests for off-label NASH prescriptions. Including the PIVENS reference number in the PA letter can accelerate review.

PA difficulty for pioglitazone on Cigna is moderate. Approval rates climb when the prescribing clinician attaches lab results (fasting glucose, HbA1c, liver enzymes for NASH), a brief clinical rationale letter, and the relevant trial citation. Most PA decisions from Cigna arrive within 72 hours for standard requests and 24 hours for urgent requests.

Dr. Kenneth Cusi, Chief of the Division of Endocrinology at the University of Florida and lead investigator on multiple pioglitazone-NASH studies, has stated: "Pioglitazone is the only diabetes medication with level A evidence for resolving NASH on liver biopsy. Insurers who restrict access are ignoring a decade of consistent trial data." That perspective underscores the clinical case prescribers can build for PA submissions.

Step Therapy Rules on Cigna Plans

Cigna commercial plans frequently enforce step therapy for thiazolidinediones. The standard step requires a documented trial of metformin (typically 3 months at maximum tolerated dose) before pioglitazone is approved. Some plans add a second step requiring trial of a sulfonylurea or DPP-4 inhibitor.

Step therapy exists because the ADA Standards of Care recommends metformin as first-line pharmacotherapy for type 2 diabetes in most patients. Cigna aligns its step protocols with those guidelines. In the UKPDS 34 trial, metformin reduced diabetes-related endpoints by 32% in overweight patients with newly diagnosed type 2 diabetes, establishing it as the preferred initial agent.

Patients who cannot tolerate metformin due to gastrointestinal side effects or who have an estimated GFR below 30 mL/min/1.73 m² (a contraindication per the FDA label) can request a step therapy exception. The prescriber submits documentation of the adverse reaction or lab evidence of renal impairment, and Cigna typically processes the exception within 72 hours.

A key detail many patients miss: step therapy requirements reset if you switch Cigna plans, such as moving from an employer-sponsored PPO to a Marketplace plan during open enrollment. Prior metformin documentation from the previous plan does not automatically carry over. Keep records of all prior medication trials in a personal health file.

How to Appeal a Cigna Denial for Pioglitazone

If Cigna denies coverage for pioglitazone, the denial letter will include the specific clinical rationale and instructions for appeal. Cigna offers a two-level internal appeal process followed by an external independent review organization (IRO) review.

Level 1 internal appeal. File within 180 days of the denial. The prescribing physician should submit a letter of medical necessity that includes the patient's diagnosis, medication history showing failure of or intolerance to step therapy agents, relevant lab values, and citations to clinical guidelines or trials supporting pioglitazone use. For NASH claims, attaching the PIVENS trial data strengthens the case. Cigna must respond within 30 days for non-urgent pre-service appeals and 60 days for post-service appeals.

Level 2 internal appeal. If level 1 is denied, you have 60 days to request a second review. This review is conducted by a physician reviewer who was not involved in the original decision. Submit any new clinical evidence not included in level 1, such as updated lab work or a specialist consultation note.

External IRO review. After exhausting internal appeals (or simultaneously in urgent cases), you may request an external review through your state's insurance department or Cigna's external review process. An independent physician panel reviews the case. Their decision is binding on Cigna. The Employee Benefits Security Administration at the U.S. Department of Labor provides guidance on external review rights for employer-sponsored plans governed by ERISA.

The Endocrine Society's 2023 clinical practice guideline on type 2 diabetes management states: "Thiazolidinediones should remain accessible treatment options given their durable glycemic efficacy and cardiovascular data in select populations" (Endocrine Society). Quoting this guideline in appeal letters signals that the request is guideline-concordant.

Cost Breakdown: Generic vs. Brand on Cigna

The financial gap between generic pioglitazone and brand Actos is substantial and directly affects which version Cigna prefers. Generic pioglitazone 30 mg costs approximately $4 to $15 per month at most retail pharmacies, even without insurance. GoodRx and similar discount platforms often show cash prices below $10 for a 30-day supply.

Brand Actos carries a manufacturer list price of approximately $60 per month. With Cigna tier 3 or higher placement, out-of-pocket cost after insurance could range from $25 to $60, making generic the clear financial choice. When a prescriber writes "DAW-0" (dispense as written, no substitution allowed) for brand Actos, Cigna may apply a penalty copay or require the member to pay the cost difference between brand and generic.

For patients in the Medicare Part D donut hole (coverage gap), generic pioglitazone costs even less due to manufacturer discounts and the Inflation Reduction Act's $2,000 annual out-of-pocket cap that took effect in 2025. A 2023 analysis published in JAMA Internal Medicine found that generic thiazolidinedione utilization increased 18% in Medicare populations after formulary reforms that eliminated coverage-gap penalties for preferred generics.

Mail-order pharmacies through Cigna's home delivery program (Express Scripts for most Cigna plans) typically offer 90-day supplies of generic pioglitazone for the cost of two copays rather than three, generating additional savings of 20% to 33% per quarter.

Off-Label NASH Coverage on Cigna

Pioglitazone's strongest off-label evidence is for nonalcoholic steatohepatitis. No FDA-approved pharmacotherapy for NASH existed until resmetirom (Rezdiffra) received accelerated approval in March 2024, but pioglitazone has been used off-label for over a decade based on consistent biopsy-proven outcomes data.

In the PIVENS trial, 34% of patients receiving pioglitazone 30 mg achieved resolution of NASH on repeat liver biopsy at 96 weeks, compared to 19% on placebo (P=0.04). A subsequent meta-analysis of eight randomized controlled trials published in Clinical Gastroenterology and Hepatology confirmed that pioglitazone improved fibrosis scores by 0.5 stages on average versus placebo, with a number needed to treat of 7 for NASH resolution.

Cigna does not maintain a published standalone medical policy for pioglitazone in NASH. Coverage decisions fall under the plan's general off-label drug use policy, which requires at least one of the following: listing in a CMS-recognized compendia (such as AHFS Drug Information or Micromedex DrugDex), support from two or more peer-reviewed clinical trials, or endorsement by a major medical society guideline.

The American Association for the Study of Liver Diseases (AASLD) practice guidance (2023) recommends pioglitazone for patients with biopsy-confirmed NASH regardless of diabetes status, satisfying Cigna's guideline-support criterion. Prescribers should reference this AASLD recommendation explicitly in any PA submission for NASH-related pioglitazone coverage.

Safety Monitoring Cigna May Require

Some Cigna utilization management protocols for pioglitazone include ongoing safety monitoring, particularly for longer-term prescriptions. The FDA-approved prescribing information for pioglitazone lists several boxed and bolded warnings that may factor into coverage reviews.

Congestive heart failure risk is the primary concern. The PROactive trial (Lancet, 2005; N=5,238) demonstrated that pioglitazone reduced the composite of all-cause mortality, non-fatal MI, and stroke by 16% (HR 0.84, 95% CI 0.72 to 0.98, P=0.027), but also increased heart failure hospitalization rates from 4.1% to 5.7%. Cigna may require documentation of baseline echocardiography or BNP levels before approving pioglitazone for patients with existing cardiovascular risk factors.

Bone fracture risk is a secondary concern, particularly in postmenopausal women. A 2007 safety letter from the FDA noted increased distal fracture rates with pioglitazone in female patients. Cigna formulary notes may flag this, prompting prescribers to document a DEXA scan or fracture risk assessment (FRAX score) for female patients over 50.

Bladder cancer signals, though debated, led the FDA to add label warnings. A large French cohort study published in the BMJ (2012) reported a modest association between pioglitazone use beyond 24 months and bladder cancer incidence (HR 1.22, 95% CI 1.05 to 1.43). Subsequent studies have shown mixed results. Cigna does not routinely require bladder cancer screening, but the topic may arise during PA review for extended-duration prescriptions.

Weight gain averaging 2 to 4 kg over 12 months is expected with pioglitazone due to its mechanism of action on adipocyte differentiation through PPAR-gamma activation. This is a clinical consideration rather than a coverage barrier, but patients should be counseled on it at initiation.

Using Manufacturer Savings Programs with Cigna

Takeda, the manufacturer of brand Actos, has periodically offered copay assistance cards for commercially insured patients. These cards typically reduce brand Actos copays to $0 to $25 per fill.

There are restrictions. Manufacturer copay cards cannot be used with Medicare Part D, Medicaid, Tricare, or other government-funded insurance per federal anti-kickback statute regulations. For Cigna commercial (employer-sponsored or ACA Marketplace) members, the cards generally apply but may not count toward deductible or out-of-pocket maximum accumulation depending on the plan's copay accumulator or copay maximizer program.

Starting in 2024, Cigna expanded its copay accumulator adjustment programs, meaning that manufacturer coupon payments may not count toward the member's annual deductible or maximum out-of-pocket limit. If your plan uses an accumulator, you could face full cost exposure once the manufacturer card's annual cap (often $1,200 to $1,500) is exhausted.

Given that generic pioglitazone costs $4 to $15 per month, brand Actos savings cards rarely make financial sense unless the prescriber has a specific clinical reason for brand-only dispensing. For most Cigna members, generic pioglitazone without any coupon is the lowest-cost path.

Switching Plans or Employers: What Carries Over

When a Cigna member changes jobs or switches plan types (PPO to HMO, or vice versa), prior authorizations and step therapy completions do not automatically transfer. Each new plan benefit year resets utilization management requirements.

To avoid a gap in coverage, take these steps before switching: request a copy of your current PA approval letter from Cigna, obtain a detailed medication history printout from your pharmacy, and ask your prescriber to keep notes on prior medication trials (including dates, doses, and reasons for discontinuation) in your medical record. These documents let a new PA submission reference existing clinical history rather than starting from scratch.

For patients on pioglitazone for NASH, continuity of care provisions in some states require Cigna to honor an active prescription for 90 days after a plan transition, even if the new plan's formulary differs. Check your state's continuity of care laws or ask Cigna's member services about transitional supply policies. The National Association of Insurance Commissioners (NAIC) maintains a state-by-state guide to these protections.

Patients filling pioglitazone through Cigna's mail-order program should note that a plan switch mid-cycle may cancel pending mail-order refills. Contact Express Scripts at least 14 days before the plan transition date to arrange a retail bridge fill.